The First Academic Committee Meeting of the Tetrahedral Framework Nucleic Acid Joint Engineering Center Held Successfully

On the afternoon of July 6, 2024, the first Academic Committee meeting of the Tetrahedral Framework Nucleic Acid Joint Engineering Center for 2024 was successfully held at Yunhai Biotechnology. The meeting was attended by distinguished guests including:

• Academician Songling Wang, Chinese Academy of Sciences

• Academician Chunhai Fan, Chinese Academy of Sciences

• Director Xuedong Zhou of the State Key Laboratory of Oral Diseases

• Professor Itamar Willner from Hebrew University of Jerusalem, Israel, and Foreign Academician of the Chinese Academy of Sciences

• Neville Compton, Editor-in-Chief of Small

• Professor Chengde Mao, Purdue University, USA

• Professor Yunfeng Lin, Deputy Secretary of the Party Committee at West China School of Stomatology, Sichuan University

• Professor Quan-Yi Guo, Orthopedic Medical Department, PLA General Hospital

• Professor Shi-Hui Zhu, Burn and Plastic Surgery Center, Shanghai Children's Medical Center

• Professor Xiaoyan Ding, Zhongshan Ophthalmic Center, Sun Yat-sen University

• Professor De-Lun Luo, President of Yunhai Biotechnology

• Mr. Song Qian, Chairman of Chuangjian Medical

• Mr. Yang Yu, Chairman of Yunhai Biotechnology

• Ms. Rong Li, Vice President of Yunhai Biotechnology

At the beginning of the meeting, Academicians Songling Wang and Chunhai Fan delivered welcome speeches, expressing their hope that the first Academic Committee meeting would provide a comprehensive platform for professionals in the field of tetrahedral framework nucleic acids, facilitating continuous innovation and rapid development in the industry.

The meeting included a report by Professor Yunfeng Lin on the key theoretical and technological research progress in framework nucleic acids. Professor De-Lun Luo presented on the progress of the industrialization and development of tetrahedral framework nucleic acids, while Yunhai Biotech’s Chairman Yang Yu provided an introduction to the operations of Yunhai Tetrahedral Biotechnology Co., Ltd. Subsequently, the academicians and professors engaged in discussions based on existing research and future directions in the field of tetrahedral framework nucleic acids.

Guests visited the headquarters of the Tetrahedral Framework Nucleic Acid Joint Engineering Center—Chengdu Yunhai Tetrahedral Biotechnology Co., Ltd. The visit included a targeted introduction to the company’s R&D achievements, industrial development plans, and patent operation model, providing guests with insight into how the company supports the transformation and industrialization of tetrahedral framework nucleic acid technology in both nucleic acid drugs and non-drug applications.

About Yunhai Biotechnology

Yunhai Biotechnology is an innovative platform enterprise based in Jinniu District, Chengdu, specializing in tetrahedral framework nucleic acids. Centered around Professor Yunfeng Lin's team from the State Key Laboratory of Oral Diseases, the company has built a general technology platform for tetrahedral framework nucleic acids based on the team’s invention of DNA tetrahedral framework nucleic acid drug systems. Yunhai Biotechnology manages and operates global patents related to tetrahedral framework nucleic acids, and collaborates with industry partners to research and develop technologies. The company is committed to advancing the conversion and industrialization of tetrahedral framework nucleic acid technologies in nucleic acid drugs and medical aesthetics.